<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A393419-8F67-4FB5-9D17-B9A04A7B3CA9"><gtr:id>5A393419-8F67-4FB5-9D17-B9A04A7B3CA9</gtr:id><gtr:name>University of New South Wales</gtr:name><gtr:address><gtr:line1>Gate 9 High St</gtr:line1><gtr:line2>Kensington</gtr:line2><gtr:line4>Sydney</gtr:line4><gtr:line5>NSW 2052</gtr:line5><gtr:postCode>2052</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ECCC96A2-526B-4202-B3E2-547EEB8FE057"><gtr:id>ECCC96A2-526B-4202-B3E2-547EEB8FE057</gtr:id><gtr:name>Newcastle General Hospital</gtr:name><gtr:address><gtr:line1>Westgate Road</gtr:line1><gtr:line2>Newcastle Upon Tyne</gtr:line2><gtr:line3>Tyne and Wear</gtr:line3><gtr:postCode>NE4 6BE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D562BA69-7B29-4D45-B446-25600A221273"><gtr:id>D562BA69-7B29-4D45-B446-25600A221273</gtr:id><gtr:name>Kagoshima University</gtr:name><gtr:address><gtr:line1>Kagoshima University</gtr:line1><gtr:line2>Korimoto</gtr:line2><gtr:postCode>890-8580</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A393419-8F67-4FB5-9D17-B9A04A7B3CA9"><gtr:id>5A393419-8F67-4FB5-9D17-B9A04A7B3CA9</gtr:id><gtr:name>University of New South Wales</gtr:name><gtr:address><gtr:line1>Gate 9 High St</gtr:line1><gtr:line2>Kensington</gtr:line2><gtr:line4>Sydney</gtr:line4><gtr:line5>NSW 2052</gtr:line5><gtr:postCode>2052</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ECCC96A2-526B-4202-B3E2-547EEB8FE057"><gtr:id>ECCC96A2-526B-4202-B3E2-547EEB8FE057</gtr:id><gtr:name>Newcastle General Hospital</gtr:name><gtr:address><gtr:line1>Westgate Road</gtr:line1><gtr:line2>Newcastle Upon Tyne</gtr:line2><gtr:line3>Tyne and Wear</gtr:line3><gtr:postCode>NE4 6BE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D562BA69-7B29-4D45-B446-25600A221273"><gtr:id>D562BA69-7B29-4D45-B446-25600A221273</gtr:id><gtr:name>Kagoshima University</gtr:name><gtr:address><gtr:line1>Kagoshima University</gtr:line1><gtr:line2>Korimoto</gtr:line2><gtr:postCode>890-8580</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B8589B0D-9E61-4F52-BF00-5D59B945DBD9"><gtr:id>B8589B0D-9E61-4F52-BF00-5D59B945DBD9</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Buckley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501898"><gtr:id>11BBB9B5-117E-442C-8DC6-2E027EB9DA2F</gtr:id><gtr:title>Autoantibodies in the pathogenesis of inflammatory and degenerative disorders of the central nervous system</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0501898</gtr:grantReference><gtr:abstractText>Limbic encephalitis (LE) is characterized by loss of memory, fitting, and confusion, and is usually untreatable. We recently discovered, however, that in a particular form of LE, antibodies generated by the patient?s own immune system (autoantibodies) targeted a protein in the brain, and seemed to cause nerve cells (neurones) to malfunction. Our discovery led us to try treatments that suppress the immune system, which significantly improved the condition of the majority of patients, and raised the possibility of treating other patients with similar disorders. The theme of this research is how autoantibodies cause brain dysfunction, and in parallel, I will study a disease where antibodies may cause loss of neurones. This condition, narcolepsy, causes sufferers to fall asleep unpredictably, and is due to death of a specific set of neurones. We have a sophisticated model system for studying the role of the immune system in narcolepsy, and by combining the laboratory studies of LE and narcolepsy, with research using samples from patients with the conditions, I hope to make important discoveries that can be translated into new treatments that may even be relevant for other common diseases associated with damage to brain neurones, such as Alzheimer?s and Parkinson?s disease.</gtr:abstractText><gtr:technicalSummary>Aims and objectives 
I will investigate pathogenic mechanisms underlying immune-mediated disorders of the central nervous system (CNS), following on from our recent ground-breaking discovery and characterisation of a novel form of limbic encephalitis (LE) that is associated with autoantibodies against voltage-gated potassium channels (VGKC-LE), and responds to immunomodulatory therapies (Buckley et al, 2001). Autoantibody-mediated diseases of the peripheral nervous system are well recognised; however, the blood brain barrier (BBB) is conventionally thought to restrict antibody pathogenicity in the CNS. Despite this, preliminary data suggest that autoantibodies have a directly pathogenic role in VGKC-LE, rather than being markers for cell-mediated immunity. This project will investigate the pathogenicity of these autoantibodies. In parallel, I will investigate the role of antibodies in a model where there is targeted loss of specific CNS neurones. Thus the project addresses both reversible and neurodegenerative aspects of CNS immunopathology, and has a broad and fundamental relevance to neuroimmunology. 
Methodology
Having demonstrated in preliminary experiments that immunoglobulins (IgG) can cross the intact BBB and enter the CNS, I will determine the effects of biological and environmental factors on the extent and distribution of IgG penetration. To investigate pathogenic effects of IgG, I will use two different models of VGKC-LE that I am currently developing. Using a wide range of techniques that my collaborators and I have already established, I will assess effects of experimental manipulations on disease phenotype and severity. Patient-derived antibodies will be used in the models, and laboratory tests will be correlated with clinical variation to further refine our understanding of the pathogenic mechanisms underlying VGKC-LE. I will apply similar techniques to investigate the interactions between humoral and cell-mediated immunity in a model of immune-mediated neurodegeneration developed with our recent MRC Brain Sciences II funding (2005). 
Scientific opportunities
The major scientific opportunities are two-fold: firstly our discovery of VGKC-LE, the first reversible CNS disease that is clearly associated with a putatively pathogenic autoantibody, provides an excellent framework for studying disease mechanism. Secondly, our unique and powerful model of immune-mediated targeted cell loss combined with our established collaborations, will allow us to address fundamental molecular, physiological and behavioural questions that will be relevant to the whole field of neurodegeneration.
Medical opportunities
The striking feature of VGKC-LE that distinguishes it from other forms of LE is the significant improvement that occurs with treatment. Understanding the pathogenesis of VGKC-LE and other immune-mediated CNS disorders could radically alter our therapeutic outlook with improved outcomes for patients.</gtr:technicalSummary><gtr:fund><gtr:end>2013-03-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-01-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>972142</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Psychiatry</gtr:description><gtr:id>43D4DF4B-A8F1-4E1E-BCF5-55E6D41EE742</gtr:id><gtr:impact>Generation of database and submission to MRC of application for randomised control trial</gtr:impact><gtr:outcomeId>54644173e4d798.02409093-1</gtr:outcomeId><gtr:partnerContribution>Characterising the psychiatric profile</gtr:partnerContribution><gtr:piContribution>Identifying patients for the cohort and delineating their antibody profile</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Neurosciences</gtr:department><gtr:description>Marco Capogna</gtr:description><gtr:id>93193F48-89AA-44CC-8740-BF423CF2E738</gtr:id><gtr:impact>21054347 Lalic Tatjana (Jan, 2011) Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission., Epilepsia. 2011 Jan;52(1):121-31.</gtr:impact><gtr:outcomeId>1777988C374-2</gtr:outcomeId><gtr:partnerContribution>Use of novel electrophysiological techniques that otherwise would not have been available to us. Revealed interesting clues to anatomy and pathophysiology.Joint applicants for further funding Improved understanding of neuropsychological aspects of disorders</gtr:partnerContribution><gtr:piContribution>Introduction to the disease and intiation of studies Provision of patient serum Immunohistochemistry Intepreting findings in light of our previous work</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of New South Wales</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Prince of Wales Medical Research Institute</gtr:department><gtr:description>Kiernan</gtr:description><gtr:id>B804BD5F-A646-4B9C-96EA-43AA9F31F672</gtr:id><gtr:impact>Publication in preparation describing the novel findings that have improved our understanding of the pathophysiology of neuromyotonia</gtr:impact><gtr:outcomeId>qSzoP6QV4fR-1</gtr:outcomeId><gtr:partnerContribution>They have provided an additional cohort of patients on which to confirm the findings on our cohort</gtr:partnerContribution><gtr:piContribution>We initiated the collaboration in order to ratify results we obtained on our cohort of patients. We have performed a battery of different assays on his cohort of patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neuropsychology Unit Oxford</gtr:department><gtr:description>Neuropsychology</gtr:description><gtr:id>C4202828-7825-46BF-BC6A-E2363932CDF5</gtr:id><gtr:impact>Publicaiton in preparation. Collaboration still very active and data gathered thus far has already altered management of patients in clinic. About to apply for funding for DPhil student to take this project further</gtr:impact><gtr:outcomeId>BF330351059-1</gtr:outcomeId><gtr:partnerContribution>Successful joint application for further funding Understanding of neuropsychology of clinical syndromes</gtr:partnerContribution><gtr:piContribution>Cosupervised research fellow. Provided clinical and immunological information to complement neuropsychology. Provided leadership and direction for joint project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kagoshima University</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:department>Department of Neurology and Geriatrics</gtr:department><gtr:description>Osamu</gtr:description><gtr:id>B31703E9-336E-4B11-BFA6-4533E89CAF03</gtr:id><gtr:impact>Publication in preparation describing the novel findings that have improved our understanding of the pathophysiology of neuromyotonia</gtr:impact><gtr:outcomeId>triXaCdQAYB-1</gtr:outcomeId><gtr:partnerContribution>They have provided an additional cohort of patients on which to confirm the findings on our cohort</gtr:partnerContribution><gtr:piContribution>We initiated the collaboration in order to ratify results we obtained on our cohort of patients. We have performed a battery of different assays on his cohort of patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Anatomical Neuropharmacology Unit</gtr:department><gtr:description>Marco Capogna</gtr:description><gtr:id>3B98782E-B84A-4597-B468-161F320F0508</gtr:id><gtr:impact>21054347 Lalic Tatjana (Jan, 2011) Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission., Epilepsia. 2011 Jan;52(1):121-31.</gtr:impact><gtr:outcomeId>1777988C374-1</gtr:outcomeId><gtr:partnerContribution>Use of novel electrophysiological techniques that otherwise would not have been available to us. Revealed interesting clues to anatomy and pathophysiology.Joint applicants for further funding Improved understanding of neuropsychological aspects of disorders</gtr:partnerContribution><gtr:piContribution>Introduction to the disease and intiation of studies Provision of patient serum Immunohistochemistry Intepreting findings in light of our previous work</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>CRUK/MRC Oxford Institute for Radiation Oncology</gtr:department><gtr:description>Radiology</gtr:description><gtr:id>2401689F-A2C9-4ADC-966B-4830EAC04868</gtr:id><gtr:impact>Pending publications Clinico-radiological protocols intiated</gtr:impact><gtr:outcomeId>7D3630259E9-1</gtr:outcomeId><gtr:partnerContribution>Specialist imaging interpretation</gtr:partnerContribution><gtr:piContribution>Indentificaion of patients and guidance on protocol</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>anderson</gtr:description><gtr:id>8768B1C3-3A31-4423-8207-AFC6D448FC78</gtr:id><gtr:impact>20113337 Anderson K N (Aug, 2010) Cerebrospinal fluid hypocretin levels are normal in idiopathic REM sleep behaviour disorder., European journal of neurology : the official journal of the European Federation of Neurological Societies 17, 8, 1105-7</gtr:impact><gtr:outcomeId>mK2CeXeN2jV-1</gtr:outcomeId><gtr:partnerContribution>They provided clinical samples for use in our assay</gtr:partnerContribution><gtr:piContribution>We assayed all the samples using the assay that was optimised as part of this research grant</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Experimental Psychology</gtr:department><gtr:description>Experimental Psychology</gtr:description><gtr:id>8B2FEDC2-1A27-4C9F-B5D0-8D396204F620</gtr:id><gtr:impact>Oral presentation at the International Society of Neuroimmunology, Sitges, 2010.</gtr:impact><gtr:outcomeId>GyVcLQwC2Ua-1</gtr:outcomeId><gtr:partnerContribution>Publication in preparation from joint experiments. They have taught us new techniques to allow us to examine the in vivo effects of our patients' antibodies.
They have also helped design future experiments and shared their expertise in modelling cognition and in hippocampal function</gtr:partnerContribution><gtr:piContribution>We initiated the collaboration and suggested the intial experiments. We have prepared and contributed the patient samples and performed all the experiments and data analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neuroscience</gtr:department><gtr:description>Cunningham</gtr:description><gtr:id>946D4132-EF9D-4672-8398-2289DBC5D49E</gtr:id><gtr:impact>Publication in press. Follow up studies now in progress.</gtr:impact><gtr:outcomeId>ff9PyW8bT3Y-1</gtr:outcomeId><gtr:partnerContribution>He has generated in vitro data to support the concept of a pathogenic effect of autoantibodies in disorders of the central nervous system</gtr:partnerContribution><gtr:piContribution>We intiated the collaboration and have contibuted patient samples, IgG preparations. In addition we have been actively involved in planning and interpreting the experiments</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Stiff Person Syndrome</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0F6816A8-8DEF-41BE-97C3-B5DA1D53FBE8</gtr:id><gtr:impact>Increased public awareness of our work

More patients requesting involvement in our research projects</gtr:impact><gtr:outcomeId>AayoisJoB9y</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Advanced Medicine Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2BA949B8-7810-4183-B0CD-C9020BEF2F63</gtr:id><gtr:impact>Royal College of Physicians Conference for several Medical Specialities. Opportunity to showcase our work to colleagues from all over the country to increase awareness of the role of autoantibodies in CNS disease. Numerous questions generated.</gtr:impact><gtr:outcomeId>56e01176c60b79.14237840</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuroradiology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>71E5F86B-DABD-4191-BAED-E797B65DECDC</gtr:id><gtr:impact>Talk generated multiple questions and subsequent email correspondence

Members of the audience contacted my after the talk to discuss further and inform me of how their practise had changed as a result of the presentation</gtr:impact><gtr:outcomeId>546449a3c77209.88687497</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MSc lectures</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F235BDF1-3EE4-407A-AA0E-220C7BFA865E</gtr:id><gtr:impact>Lectures on local MSc courses and national FRCPath courses.

Increases awareness of field and leads to requests to join laboratory group</gtr:impact><gtr:outcomeId>Mpv8jSRQSZk</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Neurosciences Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DDE09F13-6C61-4833-82EE-B3F0F3E9DB2B</gtr:id><gtr:impact>increased awareness of our research activity for a broad ranged of neuroscientists and neurologists.

Expression of interest from students keen to undertake postgraduate degrees.</gtr:impact><gtr:outcomeId>eVtEfrkC9c9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain awareness week</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>877671EA-CC03-433C-B4E8-F36ED42E2A78</gtr:id><gtr:impact>Brain Awareness week in the atrium of the neurosciences hospital publicising clinically related research to interested members of the public.

Stimulated patient enquiries for further information about the on-going research.</gtr:impact><gtr:outcomeId>bEhzp8tzGAf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.neuroscience.ox.ac.uk/</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>6957</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>E P A Cephalosporin Fund</gtr:department><gtr:description>Abraham Scholarship/St Cross College University of Oxford</gtr:description><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>0EECA16F-A91E-40FF-AD26-27ADFC1FEF6D</gtr:id><gtr:outcomeId>JsPyL2auEyr0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in clinical reviews</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C72FCC5C-22E3-4DCA-A755-93A4078FC4F0</gtr:id><gtr:impact>The increased recognition and further understanding of these disorders is increasingly disseminating into international clinical practise resulting in improved pateint outcomes as a consequence</gtr:impact><gtr:outcomeId>rvuNJWB76VH</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Published guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AA77BCFC-5C2F-4516-AE51-343EA5F0B57B</gtr:id><gtr:impact>These guidelines have significantly improved the early recognition and appropriate treatment of autoimmune encephalopathies with improved outcomes for patients, and reduced spending for the NHS.</gtr:impact><gtr:outcomeId>BacQJY6Yh5C</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>We are assisting Euroimmune in the development of diagnostic slides for multiple antibody testing on patients with encephalitis</gtr:description><gtr:id>41821D71-4117-4983-B132-66CCB417ECDA</gtr:id><gtr:impact>When in routine clinical use these slides will greatly enhance the speed, accuracy and availability of diagnosis of autoimmune encephalopathy in critically ill patients and therefore reduce morbidity and mortality by ensuring prompt administration of appropriate immunotherapy.</gtr:impact><gtr:outcomeId>TSBFj43ykko</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Euroimmune</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Identifying patient samples whom IgG binds to the surface of neuronal cultures, indicating the presence of a pathogenic antibody. This sample is used for immunoprecipitation from cultured cells, to isolate IgG-antigen complexes, which can be processed with western blotting and mass spectrometry techniques to identify novel autoantibodies.</gtr:description><gtr:id>36B5CC32-9802-4AD8-B566-C999B0413290</gtr:id><gtr:impact>Identification of a novel antibody which may be developed into a new diagnostic test, which will be invaluable in the clinical management of challenging patients.</gtr:impact><gtr:outcomeId>UmGedwjcd6w</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Immunoprecipitation/Western blot/ Mass-spectrometry</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have collected serum and in some cases CSF samples on patients with autoimmune encephalopathies. In most cases we have serial samples and associated detailed clinical information .</gtr:description><gtr:id>6E04B984-632D-42EB-AAB5-AAB6A81D0C09</gtr:id><gtr:impact>We have expanded the clinical phenotype of these disorders and therefore ensured that immunosupressive treatments are sucessfully administered to many patients who previously would not have received them. By detailed longitudinal clinical and serological studies we have generated modified treatment protocols that we have disseminated nationally. This has also led to several peer reviewed research papers in high impact journals ( including Brain and Annals of Neurology) describing new clinical phenotypes and the immunobiology underlying them.</gtr:impact><gtr:outcomeId>gJ7sMBadtQY</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Database</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Lgi1 is a secreted protein. Anchoring Lgi1 to the membrane using a fragment of a transmembrane sequence from a neuronal protein, Caspr2, increases the concentration of Lgi1 thus better sensitivity for an assay against this target.</gtr:description><gtr:id>2EB928B5-1886-41C1-A15B-34B037C3ABD8</gtr:id><gtr:impact>It has enabled accurate diagnosis in 10% of the cohort that were previously undiagnosed. This significantly changes clinical management of these patients This is now routinely used in clinical assessment of patients and additionally for monitoring of treatment response.</gtr:impact><gtr:outcomeId>cdDGRTmDgPb</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Lgi1-C2 tail cDNA</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3E2DF968-AC52-4C64-841F-EB46DA31C1F1</gtr:id><gtr:title>Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32d68ec8aec7672f0b88995be79ce83f"><gtr:id>32d68ec8aec7672f0b88995be79ce83f</gtr:id><gtr:otherNames>Irani SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>AnSrjSV3H2p</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56F2F872-7056-45C9-A0B8-1295F9D1AEA1</gtr:id><gtr:title>Republished review: Autoantibody testing in encephalopathies.</gtr:title><gtr:parentPublicationTitle>Postgraduate medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/056d842d169854930e5220ad3da15f14"><gtr:id>056d842d169854930e5220ad3da15f14</gtr:id><gtr:otherNames>Lee R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0032-5473</gtr:issn><gtr:outcomeId>pm_16209_29_22523311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC78C1AA-FEB8-47BD-8186-5EC6AE41805C</gtr:id><gtr:title>Cerebrospinal fluid hypocretin levels are normal in idiopathic REM sleep behaviour disorder.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bad80de2feabbbdf562d8da04879055d"><gtr:id>bad80de2feabbbdf562d8da04879055d</gtr:id><gtr:otherNames>Anderson KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>okasX5Peoaq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0B1F47F-3BC6-4735-BC0C-21D6753A1AE9</gtr:id><gtr:title>Autoantibody testing in encephalopathies.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/056d842d169854930e5220ad3da15f14"><gtr:id>056d842d169854930e5220ad3da15f14</gtr:id><gtr:otherNames>Lee R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>pm_16209_29_22258167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58BB4F45-533C-43B5-B893-4123C10B4203</gtr:id><gtr:title>Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0b6ef76225dc642b86c7e03e3cfd59"><gtr:id>aa0b6ef76225dc642b86c7e03e3cfd59</gtr:id><gtr:otherNames>Rodr?guez Cruz PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>56e00ee382d9e0.21741893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F8F8416-A6C7-4D9D-A25E-A7C0C93DBDE5</gtr:id><gtr:title>N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b31151178f040d941d7cbc5a93e43c7"><gtr:id>2b31151178f040d941d7cbc5a93e43c7</gtr:id><gtr:otherNames>Hacohen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_16209_29_24014096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F54E8B4F-E25D-4E94-823B-5548E132CFC9</gtr:id><gtr:title>Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32d68ec8aec7672f0b88995be79ce83f"><gtr:id>32d68ec8aec7672f0b88995be79ce83f</gtr:id><gtr:otherNames>Irani SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>fV49zP5vTbn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE0271FE-B2F1-4FD5-99DF-DDA970FD08B0</gtr:id><gtr:title>Immunization against GAD induces antibody binding to GAD-independent antigens and brainstem GABAergic neuronal loss.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209f39b43a0a141b3a9fcc985f600ddd"><gtr:id>209f39b43a0a141b3a9fcc985f600ddd</gtr:id><gtr:otherNames>Chang T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54643d5557ccf7.41388258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2B2E820-47CE-42F4-91B0-0554B945E814</gtr:id><gtr:title>Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6de0cf39546b886a007792ec7bf07dd3"><gtr:id>6de0cf39546b886a007792ec7bf07dd3</gtr:id><gtr:otherNames>Loukaides P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>HUnGLc1A5FH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38AEF180-9E1D-4D29-A8F4-701C23EEE93B</gtr:id><gtr:title>Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c07a2cd5141499e3dde9061d97e21333"><gtr:id>c07a2cd5141499e3dde9061d97e21333</gtr:id><gtr:otherNames>Zandi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>56e00e47391fe6.69849570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5F67D6D-81E4-4B57-B07C-1FFA5AE424DF</gtr:id><gtr:title>Morvan syndrome: clinical and serological observations in 29 cases.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32d68ec8aec7672f0b88995be79ce83f"><gtr:id>32d68ec8aec7672f0b88995be79ce83f</gtr:id><gtr:otherNames>Irani SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>pm_16209_29_22473710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FFB5740-C35A-4836-9390-E882F8C4CF7E</gtr:id><gtr:title>Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32d68ec8aec7672f0b88995be79ce83f"><gtr:id>32d68ec8aec7672f0b88995be79ce83f</gtr:id><gtr:otherNames>Irani SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_16209_29_24014519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51DC5DEB-38B9-4FD9-8387-34946C72B399</gtr:id><gtr:title>Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa92ea8d8f59bb90370c87f200cdd925"><gtr:id>aa92ea8d8f59bb90370c87f200cdd925</gtr:id><gtr:otherNames>Lang B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>58ca74edc44db9.54464379</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46659542-C4A4-4765-A30E-37F682F79DC1</gtr:id><gtr:title>Immunotherapy-responsive seizure-like episodes with potassium channel antibodies.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32d68ec8aec7672f0b88995be79ce83f"><gtr:id>32d68ec8aec7672f0b88995be79ce83f</gtr:id><gtr:otherNames>Irani SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>3991728B51C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D161DC6-2834-464D-8F2C-809FDFD65CD1</gtr:id><gtr:title>Immune or Genetic-Mediated Disruption of CASPR2 Causes Pain Hypersensitivity Due to Enhanced Primary Afferent Excitability.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32a388815089d258611a872ff9c2dd96"><gtr:id>32a388815089d258611a872ff9c2dd96</gtr:id><gtr:otherNames>Dawes JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>5aa8fdc3221fc8.05871291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34C64535-DAC5-4EE3-ABAE-0EAE1856B9F3</gtr:id><gtr:title>Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0f38a3975c5f02501f80fc8a4420843"><gtr:id>a0f38a3975c5f02501f80fc8a4420843</gtr:id><gtr:otherNames>Lalic T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>BAcpvt7iZie</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>704AAA37-1385-407A-A82C-AE3EB4EF5821</gtr:id><gtr:title>Persistent anterograde amnesia following limbic encephalitis associated with antibodies to the voltage-gated potassium channel complex.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08c1fddf129689a9fb04a4de77a4a411"><gtr:id>08c1fddf129689a9fb04a4de77a4a411</gtr:id><gtr:otherNames>Butler CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>54643d15b35e41.09470191</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F82F5D3-63F3-4B43-9023-5EF8FC8989E6</gtr:id><gtr:title>Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d565170e4417b15dd3b581315371bba"><gtr:id>9d565170e4417b15dd3b581315371bba</gtr:id><gtr:otherNames>Solomon T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>pm_16209_29_22120595</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AA3B1E7-D0E6-4DC8-8CA1-57488911FC5D</gtr:id><gtr:title>Clinical spectrum of voltage-gated potassium channel autoimmunity.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/574f973bede4fd9f446edfa9f6f58020"><gtr:id>574f973bede4fd9f446edfa9f6f58020</gtr:id><gtr:otherNames>Vincent A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>1102B5FF2BB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64466622-9975-4BCC-BF47-53062299F632</gtr:id><gtr:title>Antibodies to the VGKC-Complex Proteins LGI1 and CASPR2 in Acquired Neuromyotonia</gtr:title><gtr:parentPublicationTitle>ANNALS OF NEUROLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/656d9b4742025e17fcc7c32d3db849f4"><gtr:id>656d9b4742025e17fcc7c32d3db849f4</gtr:id><gtr:otherNames>Buckley Camilla</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>T6ARvmo5WGW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB558218-A123-4A7F-8F68-A048B521B2A3</gtr:id><gtr:title>Autoantibodies to GAD and Cell Surface Determinants in Stiff Person Syndrome</gtr:title><gtr:parentPublicationTitle>NEUROLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2849a93fac1dfc4386fd9716cafac4a1"><gtr:id>2849a93fac1dfc4386fd9716cafac4a1</gtr:id><gtr:otherNames>Chang Thashi</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>dvnshhoG6Wm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>654F01AA-6713-42DA-A375-F9E6129A812F</gtr:id><gtr:title>NMDA receptor antibodies associated with distinct white matter syndromes.</gtr:title><gtr:parentPublicationTitle>Neurology(R) neuroimmunology &amp; neuroinflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b31151178f040d941d7cbc5a93e43c7"><gtr:id>2b31151178f040d941d7cbc5a93e43c7</gtr:id><gtr:otherNames>Hacohen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2332-7812</gtr:issn><gtr:outcomeId>54643baa02e452.14503073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B0A3BDB-BCCA-4FF2-A908-1F79CE93D43A</gtr:id><gtr:title>Adaptive sugar sensors in hypothalamic feeding circuits.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2052982e09053c07158b4473ba838ee7"><gtr:id>2052982e09053c07158b4473ba838ee7</gtr:id><gtr:otherNames>Williams RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>Zo4122h4aFA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>417C29EC-E450-411F-AA26-83BEE38240F8</gtr:id><gtr:title>Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49a5a55005682573810740bce565abd5"><gtr:id>49a5a55005682573810740bce565abd5</gtr:id><gtr:otherNames>Leite MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16209_29_22551731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>392A1966-791B-4F74-99D6-B9972FC15C67</gtr:id><gtr:title>Antibodies to GABAA receptor a1 and ?2 subunits: clinical and serologic characterization.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f5c3d86a7c35fdc46c708e1ac35d880"><gtr:id>8f5c3d86a7c35fdc46c708e1ac35d880</gtr:id><gtr:otherNames>Pettingill P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56e00e46ef1752.77743762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EDA22FB-64B4-45E5-8EA6-A0B915E0E6EE</gtr:id><gtr:title>MORVAN'S SYNDROME: CLINICAL AND SEROLOGICAL FINDINGS IN 27 CASES</gtr:title><gtr:parentPublicationTitle>EUROPEAN JOURNAL OF NEUROLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/535e718b51c2e5f9e15e0c49aabeaf1e"><gtr:id>535e718b51c2e5f9e15e0c49aabeaf1e</gtr:id><gtr:otherNames>Irani S. R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>aNSYgBgY2EK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05D67370-35DB-4A69-BDB0-8EDDF9957E3E</gtr:id><gtr:title>Modelling autoimmune narcolepsy in humanised mice</gtr:title><gtr:parentPublicationTitle>JOURNAL OF NEUROIMMUNOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4415222071d5efacf9d94c0dd87df94e"><gtr:id>4415222071d5efacf9d94c0dd87df94e</gtr:id><gtr:otherNames>Haris Alexopoulos</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>Mta2QtVvJ7t</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501898</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>